Joint Meeting - Nonprescription Drugs Advisory Committee &
Pulmonary - Allergy Drugs Advisory CommitteeMay 11, 2001
Petition 98P-0610/CP1 - submitted
by Blue Cross of California requesting
fexofenadine hydrochloride, loratadine and cetirizine hydrocholoride be switched
to OTC status
Open Public Hearing
Eric J Schenkel, MD, Valley Allergy and Asthma Treatment Center pdf htm
Steven Weinstein, MD, University of California at Irvine pdf htm
Importance of Accurate Diagnosis of Allergy Prior to Use of Second-Generation Antihistamines, Ivor Emanuel, MD, University of California, representing Pharmacia Diagnostics pdf htm
Daniel A Hussar, PhD, University of the Sciences in Philadelphia pdf htm
Charles Cutler, MD, American Association of Health Plans pdf
Frank Brocato, Employers Health Coalition pdf htm
Mark Cloutier, MPH, MPP, RXHealthValue pdf htm
Michael Parker, MD, American Academy of Otolaryngic Allergy (AAOA) pdf
Bobby Lanier, MD, American Academy of Asthma, Allergy and Immunology (AAAAI) and College of Allergy, Asthma and Immunology pdf htm
Presentation Opposing the Switch of Fexofenadine Hydrochloride, Loratadine and Cetrizine Hydrochloride to OTC Status Due to Safety Issues, J A Quel, MD, Hispanic American Allergy, Asthma, Immunology Association (HAAMA) pdf htm
Michael Kaliner, MD, World Allergy Association pdf htm
Nancy Sander, Allergy and Asthma Network Mothers of Asthmatics pdf htm
Statement by Steven Sesterhenn, MD, MBA pdf
Phil Walson, MD, University of Cincinnati, representing Whitehall Robins pdf htm
Bryan R Luce PhD, MBA, MEDTAP International pdf htm
Joel W Hay PhD, Value in Health pdf htm
Steve Francesco, Francesco International ppt htm
Steve Francesco, newsletter SWITCH pdf htm
Bertram A Spilker, PhD, MD, Pharmaceutical Research and Manufacturers of American (PhRMA) pdf htm
R William Soller PhD, Consumer Healthcare Products Association pdf